The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.

The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced on Thursday ...

The new guidance builds on previous years’ by increasing the focus on transparency and expanding, per statute, to include details about how Medicare Part B drugs and renegotiation processes will be ...

The Centers for Medicare & Medicaid Services has postponed its BALANCE pilot program for GLP‑1 obesity drug coverage until at least 2027 after insurers balked at costs and risks. In its place, CMS ...